Search

This study aimed to validate the anti-obesity effect of okara, a soyfood byproduct, in diet induced obese mice. Thirty two C57BL/6J male 4 week old mice were divided into four dietary groups (n=8) fed either normal diet (ND), high fat diet (HD), HD with 10% okara (OL), or HD with 20% okara (OH) for 12 weeks. Body weight gain and epididymal fat weight of OL and OH group were significantly lower than HD group. Similarly, the serum and hepatic lipid profiles in OH were significantly lower than HD group. The fecal triacylglycerol and TC levels in OL and OH increased compared to HD. Also, the expression of PPAR-α was higher in OH than HD group; PPAR-γ and FAS levels were lower in OH compared to HD. In this study, okara consumption appears to protect mice against diet induced obesity (DIO) and metabolic dysregulation related to obesity.

Background Metabolic syndrome is a set of disorders that increases the risk of developing cardiovascular disease. The primary target of treatment of patients with metabolic syndrome is therapeutic lifestyle change. Numerous preclinical study have reported positive effects of chungkookjang in in vivo models of diabetes and obesity, but there is a paucity of controlled clinical trials on variables of metabolic syndrome in obese subjects. Thus, the objective of this trial is to examine the effect of chungkookjang compared to placebo on variables of metabolic syndrome in overweight/obese subjects. Methods This double-blind randomized controlled crossover trial will be conducted on 120 overweight/obese subjects; aged 19–29 years. Subjects will be recruited from the Chonbuk National University, Jeonju, South Korea. Enrolled subjects will be randomly assigned to two groups of equal number; one group received 35 g of chungkookjang (n = 60) and the other group received placebo (n = 60) on a regular daily basis for 12 weeks. After a 12-week washout period, the groups will be crossed over. In addition to anthropometric measures and blood pressure, glucose parameter, lipid profile, adipocytokine, and carnitine assay will be determined at baseline and 12 week. Also, safety will be assessing by measuring total bilirubin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, total protein, albumin, blood urea nitrogen, creatinine, and creatine kinase at baseline and 12 weeks. 24-hour dietary recalls were collected at the baseline and at the end of the trial. Discussion This trial will evaluate the effects of chungkookjang on variables of metabolic syndrome in overweight/obese subjects. The results of this study may contribute to the reduction of risk factor for metabolic syndrome caused by obesity. Trial registration Clinical trials NCT01811511.